Assessment of a vaccine in our SARS-CoV-2 NHP model : latest scientific communication12 September 2022
We are pleased to unveil the latest scientific communication related to the evaluation of an innovative heterologous recombinant heterodimer protein based vaccine in Cynbiose’s NHP SARS-CoV-2 model.
Preclinical efficacy, safety, and immunogenicity in cynomolgus macaques of the PHH-1V COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2.
Moros A, Fernández A, Bech-Sabat G, Barreiro A, Garriga C, Pradenas E, Marfil S, Blanco J, Sisteré M, Meyerhans A, Confais J, Toussenot M, Contamin H, Pizzorno A, Rosa-Calatrava M, Prat T, Roca M, March R, Prenafeta A, Ferrer L. Spanish Society for Virology national congress, Sept 6-9, 2022.
The vaccine is currently under review by the European Medicines Agency (EMA) preceding a possible marketing authorisation of the vaccine.
This model was developed in 2020 in collaboration with the VirPath Laboratory and VirNext technological platform specializing in virology and respiratory viruses.
The efficacy NHP model is relevant for testing immunotherapies, vaccines and antivirals. Several variants of the SARS-CoV-2 virus are available including omicron variant. Please contact us to discuss your project.